CO2019013212A2 - Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica - Google Patents
Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémicaInfo
- Publication number
- CO2019013212A2 CO2019013212A2 CONC2019/0013212A CO2019013212A CO2019013212A2 CO 2019013212 A2 CO2019013212 A2 CO 2019013212A2 CO 2019013212 A CO2019013212 A CO 2019013212A CO 2019013212 A2 CO2019013212 A2 CO 2019013212A2
- Authority
- CO
- Colombia
- Prior art keywords
- dimiracetam
- composition
- synergistic compositions
- racemic ratio
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a una composición de enantiómeros de 3,6,7,7a-tetrahidro-1H-pirrolo[1,5-a]imidazol-2,5-diona y solvatos o co-cristales farmacéuticamente aceptables del mismo en una cierta proporción, una composición farmacéutica que comprende dicha composición, su uso como un medicamento y el uso de las composiciones inventivas o composiciones farmacéuticas en el tratamiento y/o prevención de una enfermedad o trastorno seleccionado generalmente y preferiblemente de neuropatía sensorial periférica, preferiblemente dolor neuropático periférico; convulsiones; depresión; o deterioro cognitivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17173760 | 2017-05-31 | ||
PCT/EP2018/064125 WO2018219977A1 (en) | 2017-05-31 | 2018-05-30 | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019013212A2 true CO2019013212A2 (es) | 2020-01-17 |
Family
ID=59053899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0013212A CO2019013212A2 (es) | 2017-05-31 | 2019-11-26 | Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica |
Country Status (32)
Country | Link |
---|---|
US (2) | US10738054B2 (es) |
EP (2) | EP3534898B1 (es) |
JP (2) | JP6810983B2 (es) |
KR (1) | KR102269493B1 (es) |
CN (1) | CN110719779B (es) |
AU (1) | AU2018276382B2 (es) |
BR (1) | BR112019025006A2 (es) |
CA (1) | CA3061274C (es) |
CL (1) | CL2019003503A1 (es) |
CO (1) | CO2019013212A2 (es) |
CY (1) | CY1123386T1 (es) |
DK (1) | DK3534898T3 (es) |
EA (1) | EA201992817A1 (es) |
EC (1) | ECSP19085426A (es) |
ES (1) | ES2825498T3 (es) |
GE (1) | GEP20227336B (es) |
HR (1) | HRP20201608T1 (es) |
HU (1) | HUE050981T2 (es) |
IL (1) | IL270833B (es) |
JO (1) | JOP20190251A1 (es) |
LT (1) | LT3534898T (es) |
MX (1) | MX2019013897A (es) |
NI (1) | NI201900122A (es) |
PE (1) | PE20200699A1 (es) |
PH (1) | PH12019502580B1 (es) |
PT (1) | PT3534898T (es) |
RS (1) | RS60957B1 (es) |
SG (1) | SG11201909720SA (es) |
SI (1) | SI3534898T1 (es) |
UA (1) | UA125703C2 (es) |
WO (1) | WO2018219977A1 (es) |
ZA (1) | ZA201906863B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190251A1 (ar) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
JOP20210082A1 (ar) * | 2018-12-04 | 2023-01-30 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد و(s)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد بنسبة غير راسيمية |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200406A (en) | 1988-02-08 | 1993-04-06 | I.S.F. Societa Per Azioni | Pharmaceutically useful 2,5-dioxo-1H-octahydroimidazo[1,2-A]azepines |
IT1233860B (it) | 1988-02-08 | 1992-04-21 | Isf Spa | Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa |
GB9123641D0 (en) | 1991-11-07 | 1992-01-02 | Isf Spa | Process |
HUP0104420A2 (en) * | 1998-12-02 | 2002-08-28 | Darwin Discovery Ltd | Therapeutic composition containing a new form of tramadol and its use |
EP1034826A1 (en) | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
ITMI20030573A1 (it) | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
US20100048605A1 (en) * | 2006-12-11 | 2010-02-25 | University Of Kentucky Research Foundation | Synergistic effects of combinations of nornicotine and opioids for the treatment of pain |
ITMI20070770A1 (it) * | 2007-04-16 | 2008-10-17 | Brane Discovery S R L | Impiego di dimiracetam nel trattamento del dolore cronico |
AU2012201853B2 (en) | 2007-04-16 | 2013-06-27 | Neurotune Ag | Use of dimiracetam in the treatment of chronic pain |
US20100249164A1 (en) | 2007-10-31 | 2010-09-30 | Renger John J | Modulation of sleep with nr2b receptor antagonists |
PL2098526T3 (pl) | 2008-02-22 | 2014-06-30 | Neurotune Ag | Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu |
US9125898B2 (en) | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
EP2598504B1 (en) | 2010-07-26 | 2014-04-16 | Neurotune AG | Process for the preparation of dimiracetam |
EP2658540A1 (en) | 2010-10-29 | 2013-11-06 | Neurotune AG | Therapeutic use of dimiracetam to prevent the hand&foot syndrome caused by sorafenib |
WO2015010217A1 (en) | 2013-07-24 | 2015-01-29 | Neurotune Ag | Dimiracetam in the treatment of depression |
JOP20190251A1 (ar) | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
-
2017
- 2017-06-16 JO JOP/2019/0251A patent/JOP20190251A1/ar unknown
-
2018
- 2018-05-30 SG SG11201909720S patent/SG11201909720SA/en unknown
- 2018-05-30 AU AU2018276382A patent/AU2018276382B2/en active Active
- 2018-05-30 EA EA201992817A patent/EA201992817A1/ru unknown
- 2018-05-30 MX MX2019013897A patent/MX2019013897A/es active IP Right Grant
- 2018-05-30 WO PCT/EP2018/064125 patent/WO2018219977A1/en unknown
- 2018-05-30 LT LTEP18728356.9T patent/LT3534898T/lt unknown
- 2018-05-30 EP EP18728356.9A patent/EP3534898B1/en active Active
- 2018-05-30 CA CA3061274A patent/CA3061274C/en active Active
- 2018-05-30 DK DK18728356.9T patent/DK3534898T3/da active
- 2018-05-30 EP EP20181525.5A patent/EP3735971A1/en not_active Withdrawn
- 2018-05-30 RS RS20201220A patent/RS60957B1/sr unknown
- 2018-05-30 KR KR1020197038320A patent/KR102269493B1/ko active IP Right Grant
- 2018-05-30 HU HUE18728356A patent/HUE050981T2/hu unknown
- 2018-05-30 PE PE2019002444A patent/PE20200699A1/es unknown
- 2018-05-30 PT PT187283569T patent/PT3534898T/pt unknown
- 2018-05-30 ES ES18728356T patent/ES2825498T3/es active Active
- 2018-05-30 UA UAA201911923A patent/UA125703C2/uk unknown
- 2018-05-30 BR BR112019025006-9A patent/BR112019025006A2/pt not_active Application Discontinuation
- 2018-05-30 SI SI201830125T patent/SI3534898T1/sl unknown
- 2018-05-30 US US15/992,529 patent/US10738054B2/en active Active
- 2018-05-30 GE GEAP201815251A patent/GEP20227336B/en unknown
- 2018-05-30 CN CN201880034236.3A patent/CN110719779B/zh active Active
- 2018-05-30 JP JP2020516950A patent/JP6810983B2/ja active Active
-
2019
- 2019-10-17 ZA ZA2019/06863A patent/ZA201906863B/en unknown
- 2019-11-18 PH PH12019502580A patent/PH12019502580B1/en unknown
- 2019-11-21 IL IL270833A patent/IL270833B/en active IP Right Grant
- 2019-11-26 CO CONC2019/0013212A patent/CO2019013212A2/es unknown
- 2019-11-27 NI NI201900122A patent/NI201900122A/es unknown
- 2019-11-29 EC ECSENADI201985426A patent/ECSP19085426A/es unknown
- 2019-11-29 CL CL2019003503A patent/CL2019003503A1/es unknown
-
2020
- 2020-07-01 US US16/918,772 patent/US20200331919A1/en not_active Abandoned
- 2020-10-05 CY CY20201100929T patent/CY1123386T1/el unknown
- 2020-10-07 HR HRP20201608TT patent/HRP20201608T1/hr unknown
- 2020-12-07 JP JP2020202501A patent/JP7157471B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
CR20190364A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
CL2019003892A1 (es) | Nuevos derivados de azaquinolina. | |
CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
CL2008001560A1 (es) | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. | |
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
CO2020001242A2 (es) | Dihidrooxadiazinonas | |
CO2019013212A2 (es) | Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica | |
UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
ES2917634T3 (es) | Derivados de urea cíclica fusionados como antagonista de CRHR2 | |
EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
CO2019009020A2 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa | |
BR112021018222A2 (pt) | Composição | |
BR112021000183A8 (pt) | Preparação medicinal para uso externo | |
CO2021007055A2 (es) | Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica | |
BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
UY37572A (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
MX2020004105A (es) | Formulacion farmaceutica. | |
PH12021551239A1 (en) | Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio | |
CL2022001015A1 (es) | Uso de compuestos de imidazopirimidina o imidazotriazina para prevención, alivio o tratamiento de trastornos cognitivos. | |
CO2024002715A2 (es) | Formulaciones de radiprodil | |
BR112022001436A2 (pt) | Formas cristalinas de derivados de pirimidino-diazepina | |
BR112022003500A2 (pt) | Formulações líquidas de rifaximina |